Description
Epclusa, a breakthrough medication for the treatment of chronic hepatitis C virus (HCV) infection, has revolutionized the landscape of HCV therapy with its high efficacy and tolerability. This once-daily oral regimen combines two potent direct-acting antiviral agents: sofosbuvir and velpatasvir. Despite its transformative impact on HCV treatment, the cost of Epclusa has been a subject of considerable discussion and concern, particularly regarding its accessibility and affordability for patients worldwide. In the United States, where healthcare costs are notoriously high, the list price of Epclusa can be daunting. As of my last update, the list price for a 12-week course of treatment with Epclusa in the U.S. typically ranges from $75,000 to $80,000 USD. This high price has raised questions about accessibility, especially for uninsured or underinsured patients. While some patients may benefit from insurance coverage, copay assistance programs, or patient assistance programs offered by the manufacturer, Gilead Sciences, others may face challenges in accessing these resources, leading to concerns about treatment access and affordability.
Epclusa Cost
